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Abstract: The currently available antifungal therapy for oral candidiasis (OC) has various limita-
tions restricting its clinical use, such as short retention time, suboptimal drug concentration and 
low patients compliance. These issues could be overcome using micro or nanotechnology. In par-
ticular, solid lipid microparticles (SLMs) resulted as a particularly promising penetration enhancer 
carrier for lipophilic drugs, such as the antifungal miconazole (MCZ). Based on these considera-
tions, cetyl decanoate (here synthesized without the use of metal catalysis) was employed together 
with 1-hexadecanol to prepare MCZ-loaded SLMs. These resulted in a powder composed of 45–300 
µm diameter solid spherical particles, able to load a high amount of MCZ in the amorphous form 
and characterized by a melting temperature range perfectly compatible with oromucosal admin-
istration (35–37 °C). Moreover, when compared to Daktarin® 2% oral gel in ex vivo experiments, 
SLMs were able to increase up to three-fold MCZ accumulation into the porcine buccal mucosa. 
The prepared SLMs were then loaded into a buccal gel or a microcomposite mucoadhesive buccal 
film and evaluated in terms of MCZ permeation and/or accumulation into porcine buccal mucosa 
by using lower doses than the conventional dosage form. The promising results obtained high-
lighted an enhancement in terms of MCZ accumulation even at low doses. Furthermore, the pre-
pared buccal film was eligible as stable, reproducible and also highly mucoadhesive. Therefore, the 
formulated SLMs represent a penetration enhancer vehicle suitable to reduce the dose of lipophilic 
drugs to be administered to achieve the desired therapeutic effects, as well as being able to be ef-
fectively embedded into easily administrable solid or semisolid dosage forms. 
Keywords: miconazole; solid lipid microparticles; penetration enhancer; oral candidiasis; buccal 
gel; buccal film; cetyl decanoate; ex vivo studies; mucosal delivery; buccal mucosa 
 
1. Introduction 
Oral candidiasis (OC) is a common oral fungal disease generally caused by Candida 
albicans. Even if Candida albicans is a physiological component of the oral cavity’s mi-
croflora when an imbalance occurs, it can cause infectious disease [1–3]. In particular, OC 
is a superficial disorder that affects the oral mucous membranes, and it is generally 
characterized by removable white plaques and generalized redness of the tissue or ero-
sive erythroplakia and leukoplakic lesions, or chronic, discrete plaque-like or nodular 
lesions, depending on the severity of the pathology. Furthermore, associated lesions (e.g., 
denture stomatitis) could be involved in the pathophysiology of the OC. Due to the wide 
damage of the mucosal surface, patients often suffer from dysgeusia, burning, tenderness 
and dysphagia. Nowadays, the accepted treatment for oral candidiasis is the use of top-
ical antifungal agents, such as miconazole [4–6]. Miconazole 
(1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole; C18H14Cl4N2O; logP: 
5.3) is a synthetic imidazole antifungal that has been used for nearly 40 years to treat 
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superficial fungal infections effectively and safely. Miconazole (MCZ) acts by damaging 
the integrity of the fungal cell membrane, altering fungal adherence and inhibiting the 
formation of germ tubes and mycelia. MCZ has potent wide-spectrum activity against 
many Candida species. Furthermore, it is also useful and effective against several species 
of Candida that are resistant to fluconazole [7,8]. Anyhow, the currently available topical 
treatment has various disadvantages and limitations restricting its clinical use. In partic-
ular, the short retention time on the oral mucosa results in the need for multiple applica-
tions each day, makes it difficult to reach effective drug concentration and thus optimal 
effects and limits the treatment compliance. Moreover, the elderly generally find the 
formulations technically difficult to apply to all the locations of the oral cavity, while 
young people also require an effective and easy-to-apply treatment [7,9]. In recent years, 
innovative dosage forms have been designed for buccal drug delivery in order to over-
come the main limitations of this administration route. Conventional dosage forms are 
generally liquid, semisolid (e.g., gels and pastes), or solid dosage forms (e.g., capsules 
and tablets). Each novel formulation aims to improve drug retention on the application 
site, ease of administration and thus treatment effectiveness and compliance [9,10]. The 
use of micro and nanotechnology should result in an innovative strategy to promote drug 
effectiveness by enhancing its penetration and accumulation into the mucosal tissue. In 
particular, solid lipid microparticles (SLMs) consist of a hydrophobic core, solid at room 
temperature, able to embed the active ingredient and dissolve or disperse into the solid 
lipid matrix. They are mainly composed of physiologically compatible and biodegrada-
ble constituents, providing well in vivo tolerability and optimal biodegradability. SLMs 
are generally characterized by good physicochemical stability, high loading capacity for 
lipophilic and poorly water-soluble molecules, ability to regulate drug release rate and 
increase its bioavailability. SLMs can also serve to protect drugs from degradation. The 
production of SLMs is also feasible at a large scale, avoiding the use of organic solvents, 
with a low production cost [11–13]. Furthermore, their similarity with the lipid constit-
uents of the mucosal tissue could result in improved interaction with the surface of ap-
plication, enhanced drug retention and accumulation into the tissue and, consequently, 
increased drug effectiveness. In addition, SLMs exhibit some interesting advantages 
compared to solid lipid nanoparticles (SLNs). The micrometric dimensions (from 20 to 
300 µm) of SLMs actually permit the obtainment of a solid free-flowing powder, stable, 
easy to handle and workable, which could represent an intermediate for the preparation 
of various solid and semisolid pharmaceutical dosage forms. Moreover, for specific ad-
ministration routes (e.g., nasal and pulmonary) or applications (e.g., skin and mucosal 
delivery), their micrometric size is the most appropriate. A wide variety of lipophilic ex-
cipients can be used to prepare SLMs. The choice of the suitable lipid carrier is of crucial 
importance when preparing these drug delivery systems, as the selected excipients will 
affect the properties of the whole preparation [13]. 
Based on these considerations, the aims of the present work are the following: pro-
pose an innovative and useful strategy to synthetized cetyl decanoate without the use of 
metal catalysis, employ the obtained pure cetyl decanoate to prepare MCZ-loaded SLMs 
with ad hoc properties (e.g., suitable melting point for buccal application) and finally 
embed MCZ-loaded SLMs into semisolid or solid formulations (gel or microcomposite 
thin film, respectively) in order to make them easily dosable and administrable. 
2. Materials and Methods 
2.1. Materials 
Miconazole (MCZ, CAS 22916-47-8) and citric acid were purchased from Farmalabor 
(Bari, Italy). Decanoic acid chloride, 1-hexadecanol, Polyvinylpyrrolidone K90 (PVP-K90) 
and (R)-(+)-limonene were purchased from Sigma Aldrich (Steinheim, Germany). 
Hydroxyethylcellulose (HEC, Natrosol™ 250 MR) was supplied by Galeno (Firenze, 
Italy). Buffer solution (pH 6.8) simulating saliva was prepared by dissolving KCl (1.50 g), 
Pharmaceutics 2021, 13, 1361 3 of 23 
 
 
KSCN (0.54 g), NaH2PO4∙H2O (0.50 g), NaHCO3 (1.50 g) and lactic acid (0.90 g) in 1 L of 
distilled water. 
Phosphate Buffer Saline solution pH 7.4 (PBS) was prepared by dissolving 2.80 g of 
KH2PO4 and 20.5 g of Na2HPO4 in 1 l of distilled water. All these components were pur-
chased from VWR International (Leuven, Belgium). Trehalose was supplied by Hayash-
ibara Shoij (Hayashibara Shoij Inc., Okayama, Japan). 
All solvents and chemicals were of analytical grade and were used without further 
purification. Porcine mucosae specimens were kindly supplied by the Municipal 
Slaughterhouse of Villabate (Palermo, Italy). 
2.2. Methods 
2.2.1. Synthesis and Characterization of Cetyl Decanoate 
Decanoic acid chloride (95.36 g, 0.5 mol) was dissolved in anhydrous dichloro-
methane (50 mL), and the clear solution was carefully added to a previously heated (60 ± 
1 °C) 1-hexadecanol (121.22 g, 0.5 mol) solution in anhydrous dichloromethane (50 mL) 
under continuous stirring. The reaction was kept at 60 ± 1 °C under reflux for 12 h. Dur-
ing the reaction, the HCl produced was eliminated by evaporation, and the precipitation 
of a product was observed. At the end of the reaction, the mixture was evaporated off 
under reduced pressure, and the crude product was washed several times in NaHCO3 
saturate solution and finally in distilled water until pH 7 was reached. The solid waxy 
mass obtained was filtered, completely dried under vacuum and repeatedly crystallized 
from acetone and ethanol until gas-chromatographic purity (>98%). Yield: >80%. Four 
recrystallizations were sufficient to produce analytically pure samples of ester. 
The characterization of the obtained product comprises NMR and FTIR analysis, as 
well as the determination of the melting point. Spectral data were in line with the ex-
pected structure. 
1H NMR and 13C NMR spectra were recorded using a Bruker Avance II 300 spec-
trometer operating at 300.12 MHz. for 1H and 75.47 MHz for 13C equipped with a 5-mm 
1H/13C dual probe. 
1H NMR (300 MHz, CDCl3): δ = 0.88 (br t, 6 H), 1.26 (br s, 38 H), 1.58–1.64 (br m, 4 H), 
2.27–2.35(t, J = 7.5 Hz, 2 H), 4.04–4.12 (t, J = 6.7 Hz, 2 H). 
13C NMR (75 MHz, CDCl3): δ = 14.15, 22.68, 25.03, 25.94, 28.66, 29.16, 29.28, 29.42, 
29.55, 29.69, 29.84, 31.91, 34.40, 64.38, 173.99. 
FTIR spectra were recorded on a Fourier Transform Infrared Spectrometer (FTIR) 
(Spectrum Two FTIR spectrometer, Perkin Elmer, Waltham, MA, USA) ranging from 
4000 to 450 cm−1 as nujol mulls. The spectra were obtained as the mean of 20 scans. IR 
(cm−1): 1737 and 1473 (ester C=O). 
The melting points (m.p.) were determined by a Büchi B-540 capillary apparatus 
(heating rate: 0.5 °C/min) and are uncorrected. 
2.2.2. Screening of 1-Hexadecanol and Cetyl Decanoate Mixtures 
Different ratios of 1-hexadecanol and cetyl decanoate mixtures (from 10:90 to 90:10 
w/w), including MCZ (10% w/w) were prepared and evaluated in terms of melting point 
and morphology of the obtained SLMs (see below) in order to highlight the best compo-
sition. 
2.2.3. Preparation of Miconazole (MCZ) Loaded Solid Lipid Microparticles (SLMs) 
To prepare the SLMs, the hot-melt technique was employed. Miconazole (10% w/w 
of the lipid mixture), 1-hexadecanol and cetyl decanoate (at various ratios) were melted 
using a heating plate (Heidolph MR 10 3001 K, Heidolph Instrument GmbH & CO., 
Schwabach, Germany) equipped with a thermostatic probe (Heidolph EKT 3001, Hei-
dolph Instrument GmbH & CO., Schwabach, Germany). Afterward, 100 mL of previ-
ously heated water (90 °C) containing NaHCO3 (0.5 g) and limonene (1 mL) were added 
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under continuous stirring (800 rpm) using a Polimix mechanical stirrer RW20, equipped 
with a digital speed indicator KCH-TRON (Kinematica, Malters, Switzerland) and a steel 
4-blade rod (diameter 4.5 cm) in order to obtain an O/W emulsion. After 2 min of constant 
stirring, the prepared emulsion was cooled by immersing the beaker into an ice bath, and 
the continuous stirring was kept until the temperature reached 10 ± 2 °C. The cooling 
procedure leads to the solidification of the oil phase, thus allowing the obtaining of the 
SLMs. The prepared SLMs were then filtered and dried at room temperature. For further 
studies, the chosen best formulation was the following: MCZ:1-hexadecanol:cetyl deca-
noate = 10:72:18 ratio. Yield 97.0 ± 0.5%, referring to the starting amount of the total lipid 
and drug mass employed. 
2.2.4. Drug Loading (DL%) and Loading Efficacy (LE%) 
A total of 5 mg of SLMs was transferred into a 5 mL volume flask, completely dis-
solved in methanol and brought to volume with fresh methanol. The amount of MCZ 
was determined spectrophotometrically (UV-VIS Shimadzu 1700 Instrument, Kyoto, Ja-
pan) at λ = 272 nm. MCZ standard solutions were used to construct the calibration curve 
(concentration range: 0.05–0.50 mg/mL; y = 1.821x + 0.041; R = 0.995). The second deriva-
tive technique was used to exclude any potential interference of the excipients employed. 
The DL% (drug loading percentage) was calculated as the amount of MCZ (mg) encap-
sulated into 100 mg of SLMs. The LE% (loading efficacy percentage) was calculated as the 
amount of MCZ (mg) actually encapsulated into the SLMs relating to the total amount of 
MCZ (mg) used. The quantification of MCZ in each SLMs batch was performed in trip-
licate. 
2.2.5. Morphological Analysis of SLMs 
To evaluate surface morphology and particle geometric characteristics, optical mi-
croscopy analysis was conducted. To collect the photographs of some representative 
samples of SLMs, a Leica M165C (Leica Microsystems, Wetzlar, Germany) optical mi-
croscope equipped with a Photometrics digital camera DFC450 and Leica application 
Suite LAS4 software (40× magnification) was used. 
2.2.6. Particle Size Evaluation 
- By Light Scattering analysis: 
The aqueous dispersion of SLMs (0.1 mg/mL) was subjected to particle size distri-
bution analysis by light scattering. Measurements were carried out at 25 ± 0.5 °C by using 
a Mastersizer 3000 instrument (Malvern Panalytical Ltd., Malvern, UK) fitted with both a 
blue (470 nm) and a red (632.8 nm) laser at a fixed scattering angle of 144°. Each experi-
ment was performed in triplicate. 
- By sieving analysis: 
The separation of the microparticles into various size fractions was carried out by 
using an Endecotts Octagon 200 test sieve shaker (Endecotts Ltd., London, UK) and 
standard mesh wire sieves (Endecotts). A series of seven standard stainless-steel sieves 
(range 45–310 µm) were arranged in the order of decreasing aperture size. Each batch 
(about 2 g) was placed on the upper sieve of the series. The sieves were mounted on the 
mechanical shaker operating for 15 min continuously. The average particles size of each 
fraction was determined as the arithmetic mean of the aperture size of the screen they 
were retained upon and the aperture size of the screen that they passed. The weight of 
separated materials was measured, and the size distribution was determined. Data were 
reported as mean ± SE of six batches. 
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2.2.7. Determination of SLM Melting Temperature Range 
Each batch of SLMs was inserted into a capillary glass, and the melting temperature 
range was investigated by a Büchi B-540 capillary apparatus (BÜCHI Labortechnik AG, 
Essen, Germany) carrying out a heating rate of 0.5 °C/min until the microparticles en-
tirely melted. Each sample was evaluated in triplicate. 
2.2.8. Differential Scanning Calorimetry (DSC) 
DSC analyses were performed by using a Perkin-Elmer Pyris Diamond (Per-
kin-Elmer, Waltham, MA, USA). Samples (about 8–10 mg) were hermetically sealed in 
Perkin-Elmer aluminum caps with the aid of a punching machine and then tested from 
−30 to 130 °C (heating rate of 10 °C/min). Indium was used as the calibration standard. 
Each analysis was performed in triplicate. 
2.2.9. Preparation of SLMs-Loaded Buccal Gel 
Trehalose (150 mg), PVP-K90 (50 g) and Hydroxyethylcellulose (HEC—800 mg) 
were added to 50 mL of previously heated distilled water (60 °C), gently stirred until 
complete dissolution of each component and then left at room temperature for 24 h, until 
a homogeneous gel was obtained. Afterward, SLMs (ratio SLMs:gel = 1:8 w/w) were 
added and manually incorporated into the previously prepared gel in order to obtain a 
homogeneous and air bubbles-free dispersion. 
The uniformity of MCZ content was assessed by UV-Vis analysis. Exactly weighted 
samples of 100 mg of gel (n = 6) were withdrawn from each batch of formulation and 
dissolved into a distilled water/methanol mixture (1:4 v/v) and then brought to volume (5 
mL) with the same solvents mixture. 
The amount of MCZ was determined at λ = 272 nm. MCZ standard solutions in dis-
tilled water/methanol (1:4 v/v) were used to construct the calibration curve (concentration 
range: 0.05–0.50 mg/mL; y = 1.689x + 0.00317; R = 0.999). 
2.2.10. Preparation and Characterization of SLMs-Loaded Buccal Thin Films 
Preparation of Hydrophilic (Empty) Buccal Thin Films 
Thin layered films, as hydrophilic matrix intended to incorporate the SLMs, were 
prepared by the solvent casting method starting from aqueous gels. Four different gel 
compositions (Table 1) were tested in order to identify the best one in terms of thinness, 
flexibility and transparency. 
Table 1. Composition of the gels employed to prepare the buccal films. 
Component Matrix-A Matrix-B Matrix-C Matrix-D 
PVP-K90 50 mg 50 mg 50 mg 50 mg 
HEC 800 mg 800 mg 800 mg 800 mg 
Trehalose - - 150 mg 150 mg 
Limonene - 750 µL - 750 µL 
Water 30 mL 30 mL 30 mL 30 mL 
Trehalose (when present) was dissolved in pre-warmed distilled water (15 mL, 45 
°C), and then PVP-K90, HEC and another 15 mL of water were added. Finally, limonene 
was added (when present). The obtained gels were left in an ultrasonic bath (Branson 
B1200, Branson Ultrasonic Corporation, Danbury, CT, USA) for 2 h in order to promote 
polymers swelling and mixing, as well as to remove any air bubble. Afterward, 5 g of 
each gel were placed into silicone molds (4.5 × 4.5 cm; area 20.25 cm2) and dried in an 
oven (StabiliTherm, Thermo Fisher Scientific) at 30 °C and 55% of humidity (analogical 
thermohygrometer VWR International, Milan, Italy) for 20 h. Finally, the obtained films 
Pharmaceutics 2021, 13, 1361 6 of 23 
 
 
were left at room temperature and humidity for 2 h and then placed in heat-sealed poly-
ethylene bags until they were used for further characterization. 
Appearance and Folding Endurance 
The hydrophilic thin layered films were subjected to visual inspection in order to 
evaluate their transparency, uniformity and absence of air bubbles. Moreover, to assess 
their flexibility, folding endurance was evaluated as described in the literature [14]. 
Briefly, each film was repeatedly folded until it breaks or folded up to 300 times (end-
point) without breaking. The number of folding allowed for each film was reported as the 
folding endurance value. 
Preparation of Microcomposite Buccal Thin Films 
To prepare SLM-loaded buccal films, 380 mg of previously prepared SLMs were 
gently mixed with 5 g of gel (C or D matrices), and the homogeneous and bubble-free 
mixture was dried as previously described. The so-formed films were left to equilibrate at 
room temperature and humidity for 2 h, then cut into disks by a biopsy punch. The 
samples were put in polystyrene disposable weighing boats, packed into polyethylene 
heat-sealed bags and stored at 8 °C to maintain the integrity of SLMs and the flexibility of 
the film. 
Uniformity Tests: Weight and Drug Content 
To evaluate buccal films uniformity, small film disks having an area of 0.5 cm2 were 
carefully obtained by using a biopsy punch. Three randomly selected disks from each 
batch were accurately weighed and then employed to evaluate drug content uniformity. 
Each film disk was completely dissolved into a distilled water/methanol mixture (1:4 v/v) 
and then brought to volume (5 mL) with a fresh solvents mixture. The amount of MCZ 
was determined by UV-VIS measurements (Shimadzu 1700 Instrument, Japan) at λ = 272 
nm using the relative blank and calibration curve (see above). The same procedure was 
performed on microcomposite buccal films loaded with empty SLMs in order to avoid 
any interference of the excipients employed. The DL% (drug loading percentage) was 
calculated as the amount of MCZ (mg) encapsulated into 100 mg of buccal film. The LE% 
(loading efficacy percentage) was calculated as the amount of MCZ (mg) actually en-
capsulated relating to the total amount of MCZ (mg) contained in the starting amount of 
SLMs used. The uniformity evaluations were performed on three batches and reported as 
mean ± SE (n = 9). 
Swelling Studies 
The extent of swelling was determined in triplicate on portions (1 cm2) of each 
SLMs-loaded buccal film by using pH 6.8 simulated salivary fluid pre-warmed at 37 ± 0.5 
°C as the soaking fluid. The samples were carefully weighed (Wd) and incubated at 37 ± 
0.5 °C in simulated salivary fluid pH 6.8 (1 mL). At definite time intervals (5, 10 and 15 
min), the exceeding fluid was gently removed by a filter paper. The swollen disk was 
then reweighed (Ws), and the swelling degree was calculated using the following equa-
tion: 
Swelling Degree (SwD) = (Ws − Wd)/Wd 
where Ws is the weight of the swollen sample after time t and Wd is the initial weight. 
Results are expressed as the mean ± SE of six experiments [15]. 
Ex Vivo Mucoadhesion Strength Measurement 
The ex vivo mucoadhesive strength evaluation of MCZ loaded films was performed 
by the modified two-armed physical balance method [16]. The inner part of the porcine 
cheek excised from just-slaughtered pigs was used as model tissue and handled without 
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any pre-treatment. The tissue was glued by cyanoacrylate resin (Super Attak Loctite®, 
Henkel Italia Srl, Milan, Italy) on a glass support (Petri dish) and placed in a thermostatic 
bath at 37 ± 1 °C, which was maintained throughout the experiment. The film’s disk (area 
0.5 cm2) was fixed using a bi-adhesive to the lower side of a rubber stopper hanging from 
the balance arm. Before starting the measurements, the porcine tissue was wetted with 50 
µL of simulated salivary fluid, and then the film was placed on the tissue so it just 
touched the mucosal surface, and a light force with a fingertip was applied for 20 s. Then, 
the measurements started 3 min after application. Two disks, taken from three different 
films, were used to perform the test, and the results were expressed as mean ± SE (n = 6). 
The grams required to detach the film from the mucosal surface provided the 
measurement of mucoadhesive strength, according to the equation: 
Force of adhesion (N) = (g × 9.81)/1000 
Then, the detachment force was calculated as follows: 
Detachment force (N/m2) = Force of adhesion (N)/Surface area (m2) 
2.2.11. Ex Vivo Evaluations 
Tissue Preparation 
Mucosal specimens, consisting of tissue removed from the vestibular area of the 
retromolar trigone (buccal mucosa) of freshly slaughtered domestic 6–8-month-old pigs 
(intended for human consumption), were collected and immediately transferred to the 
laboratory in a refrigerated transport box within 1 h of animal sacrifice. Excesses of con-
nective and adipose tissue were trimmed away, and then specimens were placed in PBS 
solution containing trehalose (5% w/v) as the cryoprotectant, left for 1 h and kept at −80 
°C for at least one week. Before the ex vivo permeation studies, the specimens were 
washed for 1 h in PBS and then subjected to thermal shock in order to obtain the buccal 
mucosa. Briefly, tissue samples were dipped for approximately 2 min in a pre-warmed 
isotonic solution (60 °C), and then the connective tissue was carefully peeled off from the 
mucosa (250 ± 25 mm thick) to obtain the heat-separated epithelium along with the intact 
basal lamina [17]. The thickness was measured using a digital micrometer (VWR Inter-
national, Milano, Italy). 
Ex Vivo Permeation Studies 
The obtained buccal mucosa was equilibrated in PBS solution for about 1 h at room 
temperature to remove biological matter that could interfere with drug analysis [18]. 
Afterwards, appropriate sections of mucosa were mounted in vertical jacketed, Franz 
type diffusion cells (Permeagear, flat flange joint, 9-mm orifice diameter, 15 mL acceptor 
volume, SES GmbH—Analysesysteme, Bechenheim, Germany), used as a 
two-compartment open model. The mucosal tissues were equilibrated at 37 ± 0.5 °C by 
adding citric acid solution with a pH of 3 (chosen in order to maximize MCZ solubility) 
in both the donor and the acceptor compartments. Hereafter, the citric acid solution was 
removed from the donor compartment and replaced with the donor samples. At sched-
uled time intervals (60 min), samples (0.5 mL) were withdrawn from the acceptor com-
partment and immediately replaced with a fresh citric acid solution in order to maintain 
sink conditions. Each experiment was carried out at 37.0 ± 0.5 °C, for 6 h and repeated six 
times. The donor samples analyzed were the following: 80 mg of Daktarin® gel 2% w/w 
(containing 1.6 mg of MCZ) employed as commercial dosage to form the reference; 15 mg 
of SLMs (containing 1.2 mg of MCZ); 2.5 mg of SLMs (containing 0.2 mg of MCZ); 22.5 
mg of SLM-loaded gel (containing 0.2 mg of MCZ); 0.5 cm2 of buccal film disk D (con-
taining 0.86 mg of MCZ). Results were reported as means ± SE. The amount of MCZ 
permeated through the porcine buccal mucosa was determined by spectrophotometric 
measurements at λ = 272 nm. MCZ standard solutions in citric acid 1 mM (pH 3) were 
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used to construct the calibration curve (concentration range: 0.02–0.50 mg/mL; y = 1.386x 
+ 0.004; R = 0.999). 
Evaluation of MCZ Amount Entrapped into the Buccal Tissue 
At the end of each ex vivo permeation experiment, the amount of MCZ entrapped in 
the mucosal tissue was extracted and quantified. Each mucosal specimen was rapidly 
washed with 5 mL of isotonic solution and then dipped in methanol (5 mL), subjected to 
sonication (Branson B1200, Branson Ultrasonic Corporation, Danbury, CT, USA) for 5 
min and maintained in the extraction solvent at room temperature for 24 h. After that, the 
extraction liquor was collected, brought to volume with fresh methanol and the amount 
of drug extracted was quantified by UV-VIS analysis. Moreover, the same procedure was 
carried out on mucosal specimens treated with 15 mg of SLMs (containing 1.2 mg of 
MCZ) whose experiments were interrupted at different time points from 1 to 6 h in order 
to evaluate the time required to saturate the tissue with the drug. 
2.2.12. Data Analysis 
Data were expressed as mean ± SE. All differences were statistically evaluated by the 
Student’s t-test with the minimum levels of significance as p < 0.05. 
3. Results and Discussion 
3.1. Synthesis and Characterization of Cetyl Decanoate 
Cetyl decanoate (synonyms: hexadecyl decanoate, cetyl caprate, decanoic acid hex-
adecyl ester; CAS 29710-34-7) is the ester between capric acid and cetyl alcohol (Figure 1; 
C26H52O2; MW 396.7 g/mol). It is an aliphatic ester without unsaturation and, therefore, 
very stable. Moreover, it shows high solubilizing power against lipophilic molecules and 
exhibits remarkable “skin feel” properties, probably due to its structural similarity with 
the lipid portions of the epidermis and mucosal epithelia [19]. It is widely used as a 
mixture under the INCI name of “cetyl esters” and as a component of mixtures of esters 
obtained from the processing of vegetable oils (see Cocoyl Caprylocaprate European 
Pharmacopoeia monograph, Ph. Eur.) both in the cosmetic and pharmaceutical fields as 
an emollient and skin conditioner. However, nowadays, nothing has been reported about 
its use as a standardized raw material aimed at conferring ad hoc properties to the ob-
tained product, nor its use for the preparation of SLMs. Additionally, several methods 
have already been reported to synthesize cetyl decanoate [20–23], but the here proposed 
synthetic approach is novel and based on the reaction of decanoic acid chloride and cetyl 
alcohol without the use of metal catalysts. 
 
Figure 1. Chemical structure of cetyl decanoate. 
The obtained purified product was subjected to several spectroscopic evaluations in 
order to demonstrate the success of the synthetic strategy and the actual complete puri-
fication from the starting unreacted products. All the 1H-NMR (Figure 2), 13C-NMR 
(Figure 3) and FTIR (Figure 4) (enlarged versions of Figures 2–4 are available as Sup-
plementary Materials) data confirm the obtainment of the desired product and its purity. 
Data were further confirmed by the melting point evaluation, which resulted in 32 °C. 




Figure 2. 1H-NMR of cetyl decanoate. 
 
Figure 3. 13C-NMR of cetyl decanoate. 




Figure 4. FT-IR of cetyl decanoate. 
3.2. Optimization and Characterization of MCZ-Loaded SLMs 
Solid lipid microparticles (SLMs) are lipid-based carriers, which derive from con-
ventional oil-in-water (o/w) emulsions by replacing the liquid oil phase with a solid (at 
room temperature) lipid component or lipid mix [13]. Due to their composition, SLMs 
could be excellent carriers for lipophilic drugs. To design SLMs, the choice of the lipid 
excipients to be used is crucial as they will affect the properties of the final drug delivery 
system in terms of both shape, dimension, homogeneity and drug loading capacity. At 
this point, one of the key factors affecting drug loading ability and drug release kinetics is 
the lipid’s miscibility in the melted status [11,12]. In this work, 1-hexadecanol and cetyl 
decanoate have been selected as lipid mixture matrices. 1-hexadecanol was chosen as the 
long-chain aliphatic alcohol having good miscibility with aliphatic esters and, at the same 
time, self-emulsifying properties [24]. Moreover, 1-hexadecanol is considered safe and, 
consequently, is widely used in dermatological products. 
As 1-hexadecanol and cetyl decanoate amounts are critical in determining the SLMs 
characteristics, various ratios were tested, ranging from 10:90 to 90:10 w/w. 
Miconazole (MCZ), a potent, lipophilic, antifungal molecule, was chosen as the 
lipophilic drug model to be conveyed by SLMs. MCZ was homogeneously embedded 
into the lipid matrix in order to obtain SLMs with the aims of promoting drug entry and 
accumulation into the epithelial tissues and potentially increase its efficacy for the topical 
treatment of OC. 
In order to maximize the drug content in the SLMs, all attempts to microencapsula-
tion have been performed considering the contribution of 10% in MCZ with respect to the 
total mass of the drug and lipids. The best results were obtained when combining 
MCZ:1-hexadecanol:cetyl decanoate in the ratio 10:72:18 w/w. 
To prepare SLMs, several methods have been reported in the literature: hot-melt 
microencapsulation technique, melt emulsification method, solvent emulsifica-
tion-evaporation method, solvent emulsification-diffusion method, double emulsion 
(w/o/w) method, sonication method, spray congealing method, supercritical fluid-based 
method and spray drying method [25–29]. In this work, the hot-melt microencapsulation 
technique was used. The lipophilic drug was dissolved into the melted lipid mix, and the 
hot clear mixture is emulsified into a pre-warmed water solution. Afterward, the ob-
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tained o/w emulsion was poured into an ice bath in order to promote quick solidification 
of the lipid phase, thus obtaining the SLMs [11,13]. 
The key factors affecting the suitability of the preparation method were the follow-
ing: the pH of the employed aqueous medium and the rate during the emulsification 
process. 
Generally, MCZ has been successfully entrapped because of its poor aqueous solu-
bility and hence low partitioning into the external aqueous phase during microsphere 
formation. However, the entrapment amount of MCZ was pH-dependent. As the pH 
value of the external phase increased, the solubility of MCZ lowered, thus increasing the 
encapsulated amount of the drug. The maximum DL% value (8 ± 0.5%) was obtained at 
pH 8.0 (due to Na2CO3). The decrease of the pH value to 7.0 dropped the SLMs drug 
content below 6%. 
The addition of a surfactant was not necessary to obtain spherical particles, probably 
due to the emulsifying activity of 1-hexadecanol. Furthermore, the insertion of limonene 
in the aqueous phase, though being immiscible with it, led to the encapsulation of very 
small amounts of terpene in SLMs, proven by the strong smell emanated by the micro-
particles when crushed between the fingers. The presence of limonene in SLMs could 
promote MCZ absorption into mucosal tissues due to its well-known properties as a 
chemical penetration enhancer [30]. 
The main other factor affecting the size distribution was the stirring rate used during 
the SLMs preparation. A restricted range of dimensional distribution and a high yield 
percentage value (97.0 ± 0.5% w/w) related to the starting material were obtained at a 
stirring speed of 800 rpm. All batches produced in such a way resulted as reproducible in 
terms of particle sizes, indicating that stirring condition, cooling rate and separation 
process were well controlled. The batches produced by increasing the stirring rate (800–
1200 rpm) resulted in a sharp decrease of the average particle size, as well as in the par-
ticle recovery yield. Recovery was lower when the particle size was smaller because 
smaller SLMs could be lost during the filtration process. Accordingly, larger particles 
were obtained by setting the stirring speed to values less than 800 rpm. However, in these 
cases, a reduction of the recovery yield was also observed due to lipid material adhesion 
to the beaker walls during the cooling process. 
The obtained optimized MCZ-loaded SLMs were subjected to further characteriza-
tion in order to evaluate the efficacy of drug encapsulation, as well as their homogeneity 
in terms of dimension and shape. 
To determine the MCZ content, UV-VIS analysis has been performed. The drug 
loading % (DL%) resulted in 8.0 ± 0.5% (w/w) and thus the loading efficacy % (LE%) value 
was 80 ± 5%. These data confirmed the suitability of the microencapsulation technique, 
even if a little but acceptable loss in MCZ was observed. The presence of MCZ into the 
microsphere was also confirmed by the FTIR analysis of MCZ loaded SLMs versus MCZ 
crystalline pure (Figure S1). 
To evaluate SLMs shape and dimension, morphological analysis has been conducted 
by optical microscopy (Figure 5). 





Figure 5. SLMs morphological analysis: photographs of some representative samples collected by 
Leica M165C (Leica Microsystems, Germany) optical microscope: (a) equipped with a Photometrics 
digital camera DFC450 and Leica application Suite LAS4 software (40× magnification); (b) manu-
ally by an external camera. 
As observable, the collected photographs confirmed the presence of spherical mi-
croparticles, approximately in the range of 100–200 µm. Moreover, the absence of irreg-
ularly shaped particles or crystalline material between the SLMs is evident, suggesting 
that no crystallization phenomena of MCZ occurred during the cooling step and the 
formation of the SLMs by the starting hot emulsion. To evaluate the dimensional distri-
bution of the microspheres, two methods were used: sieves and light scattering analyses. 
The first provided information on the size distribution of the coarse particles and simul-
taneously enables the separation of the particles according to classes, highlighting the 
potential presence of non-spherical aggregates of lipid material (Table 2). The second 
method provided information on small particles that cannot be measured by sieving (see 
Figure S2 in the Supplementary material to observe the particle size distribution graph). 
Table 2. Size distribution by sieving expressed as percent ± SE (n = 6). 
Particle Size Faction (µm) SLMs in Each Fraction (% ±SE) 
>310 0.33 ± 0.01 
250–310 10.02 ± 0.31 
200–250 22.40 ± 0.68 
125–200 48.00 ± 1.24 
90–125 4.85 ± 0.15 
45–90 7.75 ± 0.22 
<45 22.40 ± 0.68 
Both sieve and light scattering analyses showed that most of the isolated SLMs were 
of the particle size range 45–310 µm. Light scattering analysis highlights that about 18% 
of the microparticles ranged from 3 to 45 µm, whereas by sieve analysis, these resulted in 
6.7%. This difference in the data is likely due to the method used. Indeed, during sieving, 
very small particles adhere to the larger ones, thus not falling into the lower sieve. The 
light scattering analysis, being in dispersion, was not susceptible to this drawback. 
These data indicate that the obtained powder is sufficiently homogeneous to handle 
and workable (e.g., processing, mixing, to be used as intermediate for semisolid or solid 
formulations) and that the prepared SLMs are small enough to distribute on the tissues 
well but not too small to be lost during application or even inhaled during handling. 
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Two other crucial characteristics to be considered and evaluated are the SLMs 
melting point as well as the physical state of MCZ (amorphous or crystalline). Both these 
evaluations could be relevant in determining the usefulness of the proposed microparti-
cles and thus the potential enhanced effectiveness of MCZ when embedded into SLMs. 
The SLMs melting point could be a key parameter. The melting points of each 
component of the SLMs and the MCZ-loaded microparticles as a whole are reported in 
Table 3. 
Table 3. Melting points of each component of SLM and MCZ-loaded SLMs. 
Compound Melting Point (°C) 
Cetyl Decanoate 32 °C 
1-hexadecanol 49.3 °C 
Miconazole 83–87 °C 
MCZ-loaded SLMs 35–37 °C 
As observable, the proposed drug-loaded SLMs showed a melting point value 
compatible with the physiological temperature of the oral cavity. This could lead to SLMs 
melting when applied strictly in contact with the buccal mucosa and, consequently, the 
release of MCZ as molecular dispersion. This could lead to an improvement in drug 
penetration into the mucosal tissue and thus increased effectiveness. 
Another relevant parameter to be considered is the physical state of the encapsu-
lated drug. Indeed, the obtainment of the amorphous form is generally preferred in order 
to promote drug solubility and, as a consequence, absorption/accumulation and efficacy. 
To evaluate whereas MCZ was amorphous or crystalline when embedded into the SLMs, 
DSC analyses were conducted. 
Figure 6A–C reports the DSC thermograms of every single component of the SLMs 
by itself. As observable, each raw material is characterized by the presence of an endo-
thermic peak related to its previously reported melting point. Figure 6D shows the 
thermogram obtained after physical mixing of all the components in the appropriate and 
selected ratio. It is possible to highlight that the simple mixing procedure already led to 
drug-excipient interactions, which allow drug amorphization. Indeed, the two endo-
thermic peaks related to cetyl decanoate and 1-hexadecanol are still present, while the 
MCZ endothermic peak is missed. This is, obviously, also observable in the SLMs ther-
mogram (Figure 6E). Moreover, it is important to notice that the ratio between the inten-
sity of the two endothermic peaks related to the excipients reflects their actual ratio in 
terms of microparticles composition (the enlarged version of Figure 6 is reported in the 
Supplementary material). 




Figure 6. DSC thermograms of: (A) pure cetyl decanoate; (B) pure 1-hexadecanol; (C) pure MCZ; 
(D) physical mix of cetyl decanoate, 1-hexadecanol and MCZ; (E) MCZ-loaded SLMs. 
3.3. Preparation of SLMs-Loaded Buccal Gel and SLMs-Loaded Buccal Film 
As the aim of this work was to propose an effective and innovative therapeutic 
strategy to replace the currently available ones in the treatment of OC while overcoming 
their relevant limitations, it is important to conceive and design an easily applicable 
dosage form having good patient compliance. Although SLMs are promising candidates 
for improving the efficacy of MCZ by enhancing its penetration into the buccal tissue, 
they consist of a powder, which could result in difficulty to evenly distribute inside the 
oral cavity, thus being not patient-friendly, leading to the administration of poorly re-
producible doses, thus compromising the therapeutic outcomes. 
From this view, the prepared MCZ-loaded SLMs were alternatively embedded into 
a buccal gel and a buccal film in order to obtain easily administrable, comfortable and 
homogeneous dosage forms. 
To prepare the SLMs-loaded gel, hydroxyethylcellulose (HEC), trehalose and 
PVP-K90 were chosen as excipients in order to obtain a homogenous, transparent and 
bubble-free gel in which to incorporate MCZ-loaded SLMs. HEC is a gelling and thick-
ening agent derived from cellulose and widely used in the cosmetic and pharmaceutical 
fields [31]. Polyvinylpyrrolidone (PVP) is a biocompatible, biodegradable, water-soluble 
polymer often used to prepare formulations with strong mucoadhesive properties 
[32,33]. Trehalose (α-D-glucopyranosyl-α-D-glucopyranoside) is a nonreducing sugar 
widely used in food, cosmetics and pharmaceutics for its unique ability to sustain and 
preserve a wide array of biological molecules due to its functions as a stress protectant, 
preventing protein degradation and preserving the cell membrane structure under stress 
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conditions [34]. In addition, new findings suggest that the targeting of the trehalose 
pathway might compromise fungal viability and virulence in Cryptococcus neoformans 
[35], indicating this sugar as a potential antifungal agent [36]. Finally, trehalose possesses 
sweetening properties suitable for diabetic patients, which could improve the palatability 
of the formulation. To enhance palatability and prevent microbial proliferation, thus ex-
tending the expiration date of the formulation, limonene was added to formulations B 
and D. Moreover, as already reported, limonene is well-known as a chemical penetration 
enhancer, and thus, it could further improve the effectiveness of the proposed formula-
tion. 
MCZ-loaded SLMs were added to the obtained optimized gel (ratio SLMs:gel = 1:8 
w/w). The obtained SLMs-loaded gel (appearance was shown in Figure S3, see Supple-
mentary Material) was evaluated in terms of drug distribution homogeneity in the sem-
isolid mass, resulting in 0.89 ± 0.04% in terms MCZ. 
To prepare the SLMs-loaded buccal film (also indicated as microcomposite), firstly, a 
screening intended to identify the best formulations was performed. Four different film 
compositions were tested starting from HEC and PVP-K90 as principal excipients and 
varying in terms of presence/absence of trehalose and limonene as further components. 
The first formulation screening step consisted of the preparation of empty buccal films 
(Table 1, see materials and methods section) to be evaluated in terms of appearance and 
folding endurance. Film A and B were immediately discharged as they were rigid and 
brittle when subjected to the folding endurance evaluation. On the other hand, films C 
and D did not show any cracks even after folding more than 300 times. Furthermore, they 
were transparent, air bubble-free and flexible. This evidence is probably due to the 
presence of trehalose, which has a high water retention capacity and thus acts as a plas-
ticizer, allowing suitable films with the desired characteristics to be obtained. In view of 
these encouraging results, two SLMs-loaded buccal films (according to C and D films 
compositions) have been prepared by the solvent casting method. 
The proposed film preparation method is simple, inexpensive and does not imply 
the use of organic solvents. The method was the most appropriate to obtain microcom-
posite formulations characterized by a homogenous dispersion of SLMs embedded into 
the hydrophilic solid matrix system resulting in highly reproducible products. The oven 
temperature to dry the prepared gel, thus obtaining the final microcomposite, was fixed 
at 30 °C to avoid SLMs melting, whereas to establish the drying time, preliminary tests 
were conducted. The best results were obtained after 20 h of drying in an oven. A drying 
procedure protracted over 28 h leads to brittle and stiff films. 
From the obtained formulations, small disks (area 0.5 cm2) were collected by the 
careful use of a biopsy punch (Figure 7) and subsequently used for further studies. 
 
Figure 7. Appearance of the SLMs-loaded buccal films and preparation of the small disks. 
The reproducibility of the films was assessed by measuring the average weight and 
drug content of three disks obtained from the same batch and repeating this procedure 
on three different batches. The obtained data are reported in Table 4. 
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Table 4. Uniformity evaluation of SLMs-loaded buccal films: weight of the obtained small disks and drug content (as a 
percentage as mg per disk) reported as means ± SE (n = 9). 
Sample Weigh of the Small Disk (mg) DL% (w/w) MCZ (mg) per Disk 
SLMs-loaded film C 11.7 ± 1.2 7.09 ± 0.94% 0.83 ± 0.11 
SLMs-loaded film D 12.3 ± 0.5 6.99 ± 0.41% 0.86 ± 0.05 
All data confirmed high product reproducibility, though the microcomposite film D 
shows slightly better characteristics. 
Another relevant parameter to be considered in the design of an effective buccal 
formulation is the swelling degree. This parameter is related to the ability of the formu-
lation to absorb water from the surrounding environment and swell, thus influencing 
film bioadhesion and drug release. Indeed, the amount of water absorbed must be the 
compromise between the development of the interactions through dosage form and 
mucosal mucins and the increase in the volume of the formulation, which, if excessive, 
could cause patient discomfort [37]. Formulations characterized by too high a swelling 
degree risk being too bulky, causing discomfort for the presence of an extraneous body in 
the oral cavity. The water uptake of the films was quantified gravimetrically at three 
different time points (5, 10 and 15 min) by using artificial saliva as the swelling fluid. 
Data are reported as a swelling degree of the SLMs-loaded buccal films, which resulted in 
a maximum after 5 min being 7.54 ± 0.91 and 6.70 ± 0.87 for SLMs-loaded film C and 
SLMs-loaded film D, respectively. After that, no more water was absorbed, and the mi-
crocomposite films remained unmodified (Figure S4). 
These results indicate that the microcomposite films, despite the presence of a lipid 
portion, are able to uptake the environmental fluids and swell, producing a dense layer 
of gel capable of retaining the SLMs on the target site. A seven or eight-fold weight in-
crease determines a variation in volume that should not be uncomfortable. Additionally, 
the application of the film could protect the OC lesions from further external insults. 
While both films were promising in terms of uniformity and swelling degree, 
SLMs-loaded film D was chosen as the final formulation to be further characterized, as it 
contains limonene, which could additionally improve patients’ compliance. 
The mucoadhesive properties of a buccal thin layer film are fundamental, as long as 
they influence the ability of the formulation to be retained on the target site avoiding in-
traoral detachment and the consequent ingestion. The bioadhesive behavior of a dosage 
form can be studied by using a wide variety of methods, which are influenced by in-
strumental variables and experiment design [38]. Here, the mucoadhesiveness of the 
proposed buccal film was measured by using an analytical balance modified according to 
the literature [16]. Data are expressed as a force of adhesion and detachment force, cal-
culated as reported in the equations described in the methods section. The force of adhe-
sion and the detachment force of SLMs-loaded film D resulted in 0.1223 ± 0.015 N and 
2446.43 ± 53.57 (N/m2), respectively, confirming suitable mucoadhesive properties. 
3.4. MCZ Permeation/Penetration Enhancement Studies: Formulations Comparison 
The final proof of concept to evaluate the possible usefulness of the proposed for-
mulations, as well as the actual effectiveness of SLMs to act as penetration and permea-
tion enhancers for a lipophilic drug, such as MCZ, consists in the ex vivo evaluation. To 
better highlight the potential of the here proposed novel dosage forms, all the prepara-
tions (SLMs, buccal gel and buccal film) were compared with a currently available, 
well-known and widely employed formulation: Daktarin® oral gel, containing 2% of 
MCZ (w/w). 
The ex vivo tests were conducted by using vertical Franz cells and porcine buccal 
mucosa. However, due to the poor solubility of MCZ in buffer pH 7.4, this cannot be used 
as a receiving fluid because it will imply the absence of the sink conditions required to 
observe the permeation phenomenon. To overcome this drawback, 1 mM citric acid so-
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lution (pH 3) was used as the acceptor fluid, as it can cause protonation of the imidazole 
ring (pKa ≈ 6.5) and, therefore, makes MCZ partially water-soluble. 
Firstly, MCZ’s ability to cross the buccal membrane was evaluated after administra-
tion of Daktarin® oral gel (80 mg = 1.6 mg of MCZ) and MCZ loaded SLMs (15 mg = 1.2 
mg of MCZ). While the amount of MCZ into the acceptor fluid was quantified at different 
time points until 6 h, at the end of each experiment, the amount of MCZ entrapped into 
the buccal tissue was also evaluated. Figure 8 reports the obtained MCZ permeation 
profile and the amount of MCZ entrapped into the mucosa after six hours of the applica-
tion of two formulations. 
 
Figure 8. MCZ (mg) after administration of Daktarin® oral gel (corresponding to 1.6 mg 
MCZ—black) or SLMs (corresponding to 1.2 mf MCZ—red): (A) permeated throughout porcine 
buccal mucosa; (B) entrapped into the porcine buccal mucosa after 6 h. Data are presented as mean 
± SE (n = 6). 
As observable, the encapsulation of MCZ into solid lipid microparticles determines 
a significant permeation enhancer effect. This is probably due to the ability of the SLMs to 
melt when kept in contact with the epithelia at 37 °C, fuse with the physiological lipids 
and penetrate the mucosa entraining the solubilized MCZ. Mucosal entrapment values 
also indicate that SLMs increase the MCZ capability of partitioning into the mucosal tis-
sue and accumulating. 
In particular, the values obtained in terms of MCZ entrapped into the membrane 
(0.0434 ± 0.0013 and 0.123 ± 0.0037 mg for Daktarin® oral gel and MCZ loaded SLMs, re-
spectively) suggested a high affinity between the SLMs components and the lipids of the 
epithelium, thus probably producing the “lipidization” of the tissue, which favors MCZ 
partition resulting in enhanced drug ability to cross the buccal mucosa due to a high 
concentration gradient between the mucosa and the acceptor fluid. 
To better understand the timing of this effect determined by the SLMs as well as to 
establish if the membrane reach a saturation condition, a set of permeation experiments 
was performed to evaluate the amount of MCZ entrapped into the buccal mucosa at dif-
ferent time points (from 1 to 6 h). 
As reported in Figure 9, the amount of drug entrapped into the tissue after the ad-
ministration of 15 mg of SLMs (1.2 mg of MCZ) grows with time until a plateau was 
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reached at 5 h (membrane saturation). The maximum amount of MCZ accumulated was 
125 µg (10.4% of the dose). 
 
Figure 9. Amount of MCZ (mg) entrapped into the buccal mucosa at different time points after the 
administration of 15 mg SLMs (corresponding to 1.2 mf MCZ). Data are presented as mean ± SE (n = 
6). 
However, the aim of a topical antifungal treatment for the OC is not to promote drug 
permeation in systemic circulation but to ensure an optimal therapeutic concentration in 
the target tissue by administering the dose sufficient to reach it. Indeed, plasma levels of 
the topically administered drug could cause adverse effects [39]. 
As the results obtained suggest the high permeation enhancing effect of SLMs, it 
should be convenient to reduce the administered dose. In this view, further ex vivo 
permeation studies were conducted by loading into the donor chamber 2.5 mg of SLMs 
(corresponding to 0.2 mg of MCZ). At the same time, the behaviors of the two proposed 
new formulations, the SLMs-loaded buccal gel and the microcomposite buccal film, ad-
ministered in comparable doses, were analyzed. In particular, the donor compartment of 
the Franz cell diffusion was filled with 22.5 mg of SLMs-loaded buccal gel (correspond-
ing to 0.2 mg of MCZ) or 12.3 mg of SLMs-loaded film disk D (corresponding to 0.86 mg 
of MCZ, 8 mm diameter according to Franz cell orifice). Figure 10 shows the cumulative 
amount of MCZ permeated after 6 h of experiment both in terms of quantity (mg) and 
percent of the administered dose. 
 
Figure 10. Cumulative amount of MCZ permeated through the porcine buccal mucosa after 6 h of 
administration, expressed as (a) amount (mg) and (b) percent of dose for: Daktarin® gel (corre-
sponding to 1.6 mg MCZ—black A); 15 mg of SLMs (corresponding to 1.2 mg MCZ—red B); 2.5 mg 
of SLMs (corresponding to 0.2 mg MCZ—blue C); 22.5 mg of SLMs-loaded buccal gel (corre-
Pharmaceutics 2021, 13, 1361 19 of 23 
 
 
sponding to 0.2 mg MCZ—green D) and 12.3 mg of SLMs-loaded buccal film (corresponding to 
0.86 mg MCZ—yellow E). Data are reported as mean ± SE (n = 6). 
As observable, the cumulative amount of MCZ (mg) in the acceptor chamber at the 
end of the experiments (6 h) is approximatively the same when administering Daktarin® 
gel, 2.5 mg of SLMs or the SLMs-loaded buccal gel. Although, it should be considered 
that in the case of Daktarin®, the administered dose is eight-fold higher than that con-
tained in 2.5 mg of SLMs or in SLMs-loaded buccal gel (1.6 vs. 0.2 mg). Moreover, when 
administering the SLMs-loaded buccal film, despite the MCZ dose was 0.86 mg, no drug 
was found in the acceptor compartment after six hours, highlighting that negligible 
permeation phenomena occur. 
Once again, at the end of the permeation experiments, the amount of MCZ en-
trapped into the buccal tissue was quantified. Indeed, as already mentioned, the goal of 
an effective topic drug delivery system to be employed in the treatment of OC is to en-
hance drug accumulation into the target tissue in order to promote in situ drug effec-
tiveness and, consequently, allow a reduction of the dose to be administered to achieve 
the therapeutic effect. In Figure 11, the cumulative amount of MCZ entrapped in the 
buccal tissue after 6 h of application is reported both as the amount (mg) (panel a) and 
percentage of the dose (panel b). 
 
Figure 11. Cumulative amount of MCZ entrapped into the porcine buccal mucosa after 6 h of ad-
ministration expressed as (a) amount (mg) and (b) percentage of the dose for: Daktarin® gel (cor-
responding to 1.6 mg MCZ—black A); 15 mg of SLMs (corresponding to 1.2 mg MCZ—red B); 2.5 
mg of SLMs (corresponding to 0.2 mg MCZ—blue C); 22.5 mg of SLMs-loaded buccal gel (corre-
sponding to 0.2 mg MCZ—green D) and 12.3 mg of SLMs-loaded buccal film (corresponding to 
0.86 mg MCZ—yellow E). Data are reported as mean ± SE (n = 6). 
These findings highlighted the penetration enhancer effect of the SLMs. The amount 
(mg) of MCZ entrapped in the buccal mucosa was always higher when it was delivered 
by the SLMs, compared to Daktarin® gel. This effect is more evident when data are ex-
pressed as a percentage of the administered dose. It is possible to make a quick and easy 
comparison between SLMs (dose 2.5 mg, blue bars) and SLMs-loaded gel (green bars) as 
they are characterized by the same MCZ starting amount (0.2 mg). It is likely to notice 
that the presence of the buccal gel slightly limits the amount of MCZ entrapped in the 
mucosa, as well as the amount of MCZ permeated (Figure 11). This is certainly due to the 
hydrophilic swellable surrounding matrix, which should be crossed by the lipophilic 
SLMs in order to get in touch with the tissue, melt and promote MCZ accumulation. 
Similar behavior is also observed for the SLMs-loaded film, considering the higher 
dose of MCZ administered. However, it should be noted that the MCZ accumulated in 
the membrane is consistent, and importantly, it represents approximately 10% of the 
administered dose. This means that the film is able to release the embedded drug for an 
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extended time, and this could lead to a reduction in the number of daily administrations 
required. 
In any case, the buccal microcomposite film is better than the conventional dosage 
form, both in the ability to enhance MCZ accumulation in the mucosal tissue and the 
capability to avoid MCZ bloodstream distribution, which could be potentially unsafe. 
Finally, as already mentioned, it is unlikely to propose the administration of free 
SLMs, and thus, a comparison between the two proposed final formulations (semisolid 
and solid) must be done. Both of the SLMs-loaded formulations are extremely promising 
as they are capable of promoting MCZ entry and accumulation into the buccal mucosa, 
allowing a reduction of the administered dose to achieve the therapeutic effect. Although 
the results obtained by applying the gel may seem better than those obtained by the film, 
the advantages of the solid dosage form should be considered. Indeed, a solid dosage 
form is more stable, easily administrable and patient-friendly compared to a semisolid 
one. Moreover, the proposed buccal film highlighted no drug permeation, and thus, no 
MCZ should be lost in the systemic circulation, and no systemic side effects should occur. 
Finally, a semisolid dosage form could be partially lost by swallowing (thus, conse-
quently, allowing drug loss), remaining, generally, in situ for a shorter period of time 
than the solid one. This is particularly true when further considering that the proposed 
buccal film was accurately designed to be mucoadhesive. 
4. Conclusions 
The here reported studies confirm all the starting aims of the present work. Firstly, 
cetyl decanoate was efficiently synthesized without the use of metal catalysis in order to 
obtain a pure raw material to be used to prepare MCZ-loaded SLMs. Furthermore, suit-
able SLMs in terms of DL%, particle size and shape were produced by the hot-melt tech-
nique after a careful modulation of some crucial parameters (e.g., pH of the aqueous 
medium and speed rate during the emulsification process). The prepared MCZ-loaded 
SLMs also emerged as promising oromucosal penetration enhancers due to their melting 
temperature range (compatible with the physiologic oromucosal temperature), also 
thanks to their ability to lead to complete MCZ amorphization. Additionally, SLMs were 
effectively incorporated into semisolid and solid formulations, which could result in easy 
administration and being patient-friendly. The ex vivo findings of the present work 
highlighted that the SLMs act as suitable penetration enhancers in any case. Indeed, the 
amount (mg) of MCZ entrapped into the buccal mucosa is always higher when it is de-
livered by the SLMs compared to Daktarin® gel, employed as a model of the conventional 
dosage form. The findings obtained are even more evident when data are expressed as a 
percentage of the dose administered. Moreover, it is likely to notice that by embedding 
the proposed SLMs into a solid or semisolid formulation, a slight reduction in terms of 
MCZ entrapment into the buccal mucosa is observed. This is certainly due to the sur-
rounding hydrophilic swellable matrix, which should be crossed by the lipophilic SLMs 
to get in touch with the tissue, melt and promote MCZ accumulation. However, it is un-
likely to propose the administration of free SLMs, and thus a comparison between the 
two proposed formulations must be reported. 
At first sight, the results obtained by the ex vivo experiments seem to suggest the 
superiority of the here proposed SLMs-loaded buccal gel. However, some key factors 
have to be considered. In particular, the SLMs-loaded buccal film allowed no MCZ per-
meation, thus totally limiting the possibility of adverse side effects due to MCZ entry into 
the bloodstream. Furthermore, the consistent amount of MCZ entrapped into the mucosa 
after the administration of the microcomposite film represents approximately 10% of the 
administered dose. This suggests that the film is able to release the drug for an extended 
period of time, consequently leading to a reduction in terms of the number of daily ad-
ministrations. 
Moreover, the SLMs-loaded buccal film could generally benefit from the advantages 
of a solid dosage form (e.g., stability, ease of administration, high patients’ compliance), 
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while also taking the advantages of an innovative DDS (e.g., mucoadhesion, which re-
sults in enhanced retention time on the administration surface vs. semisolid dosage 
forms, which could be partially lost by swallowing). 
5. Patents 
The work reported in this manuscript is part of an Italian patent application n. IT 
201900011436 by Viviana De Caro and Libero Italo Giannola. 
Supplementary Materials: The following are available online at 
www.mdpi.com/article/10.3390/pharmaceutics13091361/s1, Figure S1: FT-IR spectra in KBr of MCZ 
loaded microspheres (red) and MCZ crystalline pure (blue). Figure S2. Dimensional distribution of 
a batch of MCZ loaded SLMs by Mastersize 3000, Malvern. Figure S3. Appearance of the 
SLMs-loaded buccal gel. Fig.S4. SLMs-loaded film D after 15 min of swelling. Figures S5–S8 are 
enlarged versions of Figures 2–4 and 6. 
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